RxDoctor Payments DataLook up a doctor →

Daniel Childs, MD

Medical Oncology · Rochester, MNNPI 1851770036

Payments from drug & device makers

$805,815in general payments, 2019–2025

Across 14 payments — averaging $57,558 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$491K
  • Amgen$183K
  • Janssen Research & Development, LLC$123K
  • Merck$5K
  • Johnson & Johnson$3K
  • Atricure, Inc.$20

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$491,168
Amgen1$183,315
Janssen Research & Development, LLC5$123,378
Merck1$5,183
Johnson & Johnson2$2,750
Atricure, Inc.1$20

How this compares

$805,815 in reported general payments places this provider in the 70th percentile of 133 medical oncology providers in Minnesota.

See all medical oncology providers in Minnesota

Medicare billing

Part B allowed, 2024
$2,522,070
Medicare patients
509
Services billed
86,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →